Areteia Therapeutics vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 36)
Areteia Therapeutics logo

Areteia Therapeutics

EmergingLife Sciences & BioTech

Respiratory & Eosinophilic Disease Therapeutics

Areteia Therapeutics (formerly TPI) is developing dexpramipexole, an oral eosinophil-depleting drug for eosinophilic asthma and EGPA; raised $215M in a Series B in 2023; Phase 3 EXHALE trial ongoing;

AI VisibilityBeta
Overall Score
D36
Category Rank
#82 of 198
AI Consensus
86%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
33
Gemini
36

About

Areteia Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral treatments for eosinophil-driven diseases, particularly severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). The company was formerly known as TPI Therapeutics and rebranded as Areteia upon securing significant venture financing. Its lead compound, dexpramipexole, is a small molecule that selectively inhibits eosinophil maturation in the bone marrow — reducing circulating eosinophil levels by 75-90% without the immunosuppressive effects that can accompany broad anti-inflammatory drugs.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#82
Category Rank
#11
86
AI Consensus
68
stable
Trend
stable
36
ChatGPT
71
33
Perplexity
68
36
Gemini
80
31
Claude
77
32
Grok
69

Key Details

Category
Respiratory & Eosinophilic Disease Therapeutics
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.